![Using Waivers to Curb COVID-19 Legal Exposure](https://media2.mofo.com/v3/images/blt5775cc69c999c255/bltf4a9e47238ab4f32/627314e0220ab5285f518fd9/02_28_elc_blog_600px_v2_image.jpg?format=auto&quality=60&width=700)
The Coronavirus Aid, Relief, and Economic Security (CARES) Act (or “the Act”) is an unprecedented $2 trillion economic stimulus package passed to help mitigate the economic and health consequences caused by the COVID-19 pandemic and to strengthen the U.S. health system going forward. The Act includes many provisions addressing specific needs that have come to light during the COVID-19 pandemic, but some of these provisions have important impacts on the drug and device industry well beyond the current pandemic. The CARES Act, unsurprisingly, also contains provisions unrelated to the COVID-19 pandemic but that have potentially significant impacts on life science and medical device companies.
Read more on our MoFo Life Sciences Blog.